ICON stock reacts to earnings update and reiterated outlook

ICON (NasdaqGS:ICLR) drew attention after reporting first quarter 2026 results and then reiterating full year revenue guidance, giving investors fresh data on current performance and management expectations for the rest of the year.

The company posted first quarter sales of US$2,034 million, with net income of US$104.75 million, followed by guidance for 2026 revenue between US$7.85b and US$8.15b.

ICON's latest earnings update and reiterated guidance come after a strong 90 day share price return of 61.5%. This is despite the year to date share price return being down 8.27% and the 3 year total shareholder return being down 29.17%, suggesting recent momentum has picked up as investors reassess growth prospects and risks.

If ICON's recent move has you thinking about other opportunities, this could be a useful moment to see what else is gaining attention in healthcare AI, starting with the 40 healthcare AI stocks.

For ICON, a 61.5% move over 90 days after mixed earnings and a reiterated outlook raises a simple tension: is the stock now echoing the underlying business, or mainly reflecting a swing in sentiment that the valuation still needs to justify?

Most Popular Narrative: 12.9% Overvalued

At a last close of $173.06 versus a narrative fair value of $153.25, ICON is framed as richly priced, with that gap hinging on a detailed future earnings story.

The analysts have a consensus price target of $153.25 for ICON based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $180.0, and the most bearish reporting a price target of just $125.0.

Want to see what kind of earnings ramp and margin rebuild have to line up for that fair value? The narrative leans on very specific growth, profitability and valuation assumptions that many investors may want to stress test for themselves.

Result: Fair Value of $153.25 (OVERVALUED)

However, ICON's story can change quickly if clinical trial cancellations stay elevated or if pricing pressure across contract research rivals eats into margins and future earnings power.

Another View on ICON's Valuation

The earlier analyst narrative frames ICON as about 12.9% overvalued against a fair value of $153.25, yet Simply Wall St's DCF model points in a different direction, with ICON trading roughly 30.6% below an estimated future cash flow value of $249.21. Which version of fair value do you trust more?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out ICON for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mixed signals around ICON leave you uncertain, this is a good time to act promptly, review the latest data and weigh the 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond ICON?

If ICON has sharpened your focus on where to put fresh capital next, do not leave it there. Use this moment to scan the market for clearer opportunities.

• Target stronger value plays by checking stocks that combine quality fundamentals with attractive pricing using the 44 high quality undervalued stocks.
• Secure more reliable income streams by reviewing companies offering higher yields and robust payout profiles through the 7 dividend fortresses.
• Prioritize stability and sleep-better-at-night holdings by focusing on companies highlighted in the 73 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.